Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.
Comparable chart history for this briefing.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not available for this company right now.
EPS
Not available
Not available for this company right now.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
1.74x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY22 vs HY21
Revenue
$0.36m
+33.8% ↑ vs $0.27m
Net profit after tax
−$2.5m
+99.9% ↑ vs −$2.3b
Net cash inflow from operating activities
−$3.7m
-88.8% ↓ vs −$2m
Operating profit
−$3.9m
+99.9% ↑ vs −$3.5b
Profit before tax
−$3.5m
+99.9% ↑ vs −$3.2b
Cash and cash equivalents
$2.3m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Total assets
$28m
-12.8% ↓ vs $32.1m
What changed
Operating outflows nearly doubled to $3.7m from $1.9m in HY21, and the headline cash balance fell to $2.3m from $19.2m a year earlier. Total assets only declined by roughly $4.1m to $28.0m over the same window, which means a large portion of the cash drawdown is reclassification within current assets (likely term deposits) rather than economic depletion of that scale.
The income statement remains pre-commercial in character. Revenue rose to $0.36m from $0.27m, but the recognition basis is not consistent across the two periods (prior was disclosed as "other income"), so the apparent uplift is not analytically clean. Loss before tax widened to $3.5m from $3.2m and loss after tax to $2.5m from $2.3m. Capex fell to $0.3m from $1.1m.
What matters
Operating cash outflow of $3.7m for the half is the more reliable read on quarterly run-rate spend than the reported loss, because the loss includes non-cash items and the company is not yet generating commercial revenue to offset operating costs. Combined with $0.3m of capex, free cash outflow pre-lease was $4.0m for the half. This matters because Rua's funding capacity, not its accounting loss, governs how long the commercialisation push can run before another capital event.
Liquidity disclosure needs interpretation. Headline cash of $2.3m looks tight in isolation, but total assets of $28.0m and equity of $26.5m, alongside an NTA per share of $0.16, suggest the bulk of IPO proceeds remain on the balance sheet in non-cash form. The investor read hinges on what portion of the $25.8m non-cash asset base is genuinely liquid versus tied up in plant, inventory build, intangibles, or restricted balances.
Commercialisation narrative still forward-looking. Management frames the period as "constructive" with "first product, first revenue imminent". That language is unchanged in tone from prior releases, so the half does not yet contain a step-change to commercial-stage economics. The result must be judged against the readiness milestones rather than against operating margins or returns.
Expectations
There is therefore nothing in this release to test against a prior numerical commitment.
What the release does support is that Rua remains in build-and-spend mode: opex has risen, capex is moderating after the prior period's plant investment, and revenue is not yet at a level that informs unit economics. What it does not support is any assessment of gross margin, recurring versus milestone mix, or the durability of demand, because those data do not yet exist at scale.
Quality of result
The reported loss is a function of pre-commercial operating spend and R&D, not of working-capital movements, one-off items, or accounting choices that could be reversed. The lack of an EBITDA disclosure and the absence of segment reporting are consistent with that pre-commercial status. There is no tax distortion concern of practical relevance, because the operating loss is the dominant signal.
The cash-flow read is the more important quality signal and it has deteriorated. Operating outflows rose materially while revenue did not, so the cash-burn ratio per dollar of revenue is not yet a useful operating metric. Capex restraint at $0.3m is a partial offset, but free cash outflow pre-lease still widened to $4.0m. The release does not provide a bridge between the $16.9m fall in headline cash and the $4.0m of free cash outflow, which is the single largest gap between reported numbers and intuitive interpretation in this result.
Unresolved
This briefing cannot assess Rua's commercial-stage unit economics, gross margin profile, or runway with precision, because the release does not disclose the liquidity composition behind the $2.3m headline cash figure or the timing and pricing of first commercial sales.
Chat
Ask follow-up questions about Rua Bioscience's HY22 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
Results Announcement
HY22 / results announcementRua Bioscience Interim Financial Statements Market Announcement
HY22 / results releaseRua Bioscience Limited Interim Financial Statements - 31 December 2021
HY22 / financial reportResults Announcement
HY21 / results announcementRua Bioscience Interim Financial Statements
HY21 / financial reportRua Bioscience Interim Financial Statements Market Announcement
HY21 / results releaseFinancial Results Announcement FY21
FY21 / results announcementRua Bioscience FY21 Annual Results Market Announcement
FY21 / results releaseRua Bioscience Limited FY21 Financial Statements
FY21 / financial reportPresentation Slides
HY22 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.